Silence Therapeutics plc filings document a foreign biotechnology issuer whose American Depositary Shares trade on Nasdaq under SLN, with each ADS representing three ordinary shares. The record includes 8-K reports furnishing quarterly and annual financial results, business highlights, Regulation FD presentations and other events tied to siRNA pipeline development.
The company’s disclosures also cover proxy materials for shareholder voting and governance, board composition, executive departures and appointments, committee changes, and the relationship between listed ADSs and ordinary shares. Clinical and business exhibits describe programs from the mRNAi GOLD platform, including SANRECO updates for divesiran in polycythemia vera and collaboration-related disclosures involving AstraZeneca.
Silence Therapeutics plc (SLN) entered into an agreement for Merck KGaA, Darmstadt, Germany to acquire all issued and to-be-issued share capital through a U.K. scheme of arrangement. Holders are to receive $20.00 in cash per ADS (each ADS represents three ordinary shares), or $6.6667 per ordinary share. The transaction is described as approximately $1.3 billion in equity value and $1.1 billion in enterprise value; the ADS consideration represents a 130% premium to the October 16, 2026 closing price and an 82% premium to the 30-day volume-weighted average price of $10.99.
The board unanimously approved the agreement. Completion is expected in the first quarter of 2027, subject to shareholder approvals, High Court sanction, expiration or early termination of the U.S. antitrust waiting period, German antitrust approval or deemed approval, and other conditions; there is no financing condition. Securityholders representing approximately 14% of voting power signed support agreements and agreed to vote in favor. Silence may owe a $13 million termination fee in specified circumstances, including if it terminates to accept a superior proposal.
Silence Therapeutics plc (SLN) is the issuer named in an amended ownership report in which Tetragon Financial Group Limited, its investment manager Tetragon Financial Management L.P., and the manager’s principals Patrick G. G. Dear and Reade E. Griffith each report the same shared beneficial ownership of 9,878,565 ordinary shares, or 5.3% of the class. The position is represented by 3,292,855 American Depositary Shares (ADSs) and includes 1,500,000 shares issuable upon exercise of call options, underlying 500,000 ADSs. Each ADS represents three ordinary shares. The 5.3% calculation uses 186,461,401 ordinary shares outstanding, as reported after completion of the offering and full exercise of the underwriters’ over-allotment option.
Silence Therapeutics plc (SLN) is named in a Schedule 13G reporting beneficial ownership of 9,708,153 ordinary shares, or 5.2%, with shared voting and dispositive power. The position is represented by 3,236,051 ADSs and includes 1,500,000 ordinary shares underlying 500,000 ADSs issuable upon exercise of call options.
Tetragon Financial Group Limited filed jointly with its investment manager, Tetragon Financial Management L.P., and the manager’s principals Patrick G. G. Dear and Reade E. Griffith. Each cover page reports the same shared position.
Richard Griffiths filed Amendment No. 11 updating his beneficial ownership in Silence Therapeutics plc ordinary shares. He reports beneficial ownership of 14,391,498 ordinary shares, representing 7.97% of the class, based on 180,628,068 ordinary shares outstanding. These holdings consist of 10,777,044 shares represented by ADSs held by Ora Capital Limited, 600,000 shares represented by ADSs held by Cream Capital Limited, and 3,014,454 shares represented by ADSs held directly by Mr. Griffiths; each ADS represents three ordinary shares. The amendment states it is being filed to reflect significant dilution from an increase in the issuer’s share capital together with open market transactions in ADSs, including the sale by Mr. Griffiths of 5,484,320 ADSs in open market transactions between August 10, 2026 and August 12, 2026 for aggregate sales proceeds of $87.
Silence Therapeutics plc is the subject of an updated ownership report by several affiliated investment entities and Raymond Debbane. As of June 30, 2026, Invus Public Equities, L.P. beneficially held 8,707,287 ordinary shares, represented by 2,902,429 American Depositary Shares (ADSs). Avicenna Life Sci Master Fund LP held 1,227,027 shares, represented by 409,009 ADSs. Each ADS represents three ordinary shares. Based on 141,703,840 shares outstanding as of April 30, 2026, Invus-related entities report beneficial ownership of 6.1% of the class and Avicenna-related entities 0.9%, while Raymond Debbane may be deemed to beneficially own 9,934,314 shares (7.0%) through his control of the reporting entities. The reporting group certifies the holdings are not for the purpose of changing or influencing control of Silence Therapeutics.
Griffiths Richard Ian reported acquisition or exercise transactions in a Form 4 filing for SLN. The filing lists transactions totaling 5,484,320 shares from August 10, 2026 to August 10, 2026.
Silence Therapeutics plc entered into an underwriting agreement on August 11, 2026 to conduct an underwritten public offering of 12,962,963 American Depositary Shares (ADSs), each representing three ordinary shares. The ADSs are priced at $13.50 per ADS to the public, with underwriters purchasing at $12.69 per ADS, under an effective Form S-3 shelf registration and related S-3MEF filing.
The company granted underwriters a 30‑day option to buy up to an additional 1,944,444 ADSs. Gross proceeds are expected to be approximately $175 million, with estimated net proceeds of about $164.0 million, or $188.7 million if the option is fully exercised, in each case after underwriting discounts and estimated expenses. The offering is expected to close on or about August 13, 2026, subject to customary conditions. Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book‑running managers.
Silence Therapeutics plc is conducting an underwritten public offering of 12,962,963 American Depositary Shares (ADSs), each representing three ordinary shares, at $13.50 per ADS, for gross proceeds of $175,000,000.50. Underwriters have a 30-day option to purchase up to 1,944,444 additional ADSs.
After underwriting discounts and estimated expenses, net proceeds are estimated at about $164.0 million, or $188.7 million if the option is fully exercised. The company plans to use the funds, together with existing cash, to continue clinical development of its siRNA product candidates and for general corporate purposes.
As of June 30, 2026, there were 141,739,180 ordinary shares outstanding (47,246,393 ADSs). The offering will cause immediate dilution of $10.32 per ADS to new investors based on a historical net tangible book value of $0.59 per ADS increasing to $3.18 per ADS after the offering.
Silence Therapeutics plc is conducting a primary offering of up to $150,000,000 of American Depositary Shares, with each ADS representing three ordinary shares. The ADSs trade on the Nasdaq Global Market under the symbol “SLN”.
The company is a biotechnology business developing short interfering RNA (siRNA) therapeutics using its proprietary mRNAi GOLD™ platform to silence disease-associated genes in the liver. It recently announced positive topline Phase 2 SANRECO results for its candidate divesiran and expects to start a Phase 3 Q12W dosing trial in the first half of 2027.
Net proceeds, together with existing cash and cash equivalents, are intended to fund continued clinical development of product candidates and general corporate purposes, including working capital, capital expenditures, investments and collaborations. Management expects this funding, combined with current cash, to support operations and capital needs into 2029, though additional capital is expected to be required to complete development of any product candidate. Investors face risks including immediate dilution, potential future equity offerings, an active-market risk for ADSs, and no anticipated dividends.
Silence Therapeutics plc reported positive topline results from the Phase 2 SANRECO trial of its siRNA candidate divesiran in 48 phlebotomy-dependent patients with polycythemia vera (PV). The 36-week, randomized, double-blind, placebo-controlled study evaluated divesiran 6 mg/kg given subcutaneously every six or twelve weeks.
The primary endpoint was met, with an 88% response rate in divesiran-treated patients versus 19% on placebo during weeks 18–36 (p<0.0001), defined as maintaining hematocrit below 45% without phlebotomies. In a sensitivity analysis (n=40), response was 89% vs 8% (p<0.0001). The mean number of phlebotomies from weeks 0–36 was 0.2 in the divesiran arm versus 2.1 with placebo (p<0.0001). Divesiran was generally well tolerated, with safety consistent with earlier studies and only two investigator-reported grade 1 anemia events.
All patients have completed the placebo-controlled portion and entered a three-year extension. Based on these results, Silence expects to initiate a Phase 3 trial in the first half of 2027, focused on Q12W dosing versus placebo.